Skip to main content

Bonesupport Holding AB (publ) (BOEUF)

OTC Markets (US) Healthcare Medical - Instruments & SuppliesView data quality →
61.2Fair

ValueMarkers Composite Index

Top 82%#7,892 of 44,722

DCF data not available

Piotroski
6/9
Neutral
Beneish
-2.60
Low Risk
Altman
7.62
Safe
DCF Value
-
N/A
ROIC
19.1%
Strong
P/E
109.3
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Bonesupport Holding AB (publ) (BOEUF) — VMCI valuation read

Headline read on BOEUF: VMCI of 61/100 versus a Healthcare sector median of 50. The 11-point above-median position is what makes Bonesupport Holding AB (publ) a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on BOEUF: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on BOEUF: value (BOEUF trades at 15.0x earnings, 17% below the Healthcare median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 1.4x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

BOEUF fell 0.2% over the trailing 7 days, with a -4.7% read on a 30-day basis.

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.

CEO: Torbjorn Skold140 employeesSEwww.bonesupport.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.